You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 61 No. 2, February 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Genetic Disorders
 •Immunologic Disorders
 •Cognitive Disorders
 •Multiple Sclerosis/ Demyelinating Disease
 •Alert me on articles by topic

Reduced N-acetylaspartate Levels and Cognitive Decline

Since this article does not have an abstract, we have provided the first 100 words of the full text and any section headings.

The report by Enzinger et al1 confirms the earlier study by Chapman et al2 regarding the predictive value of the apolipoprotein E {epsilon}4 allele (APOE {epsilon}4) for severity in multiple sclerosis. Reduced N-acetylaspartate levels have been shown to be valuable markers for cognitive decline in several diseases, including Alzheimer disease3-4 and multiple sclerosis5 (C. Christodoulou, PhD, L. B. Krupp, MD, Z. Liang, PhD, et al, written communication, 2003). Were any data collected by Enzinger and colleagues on cognitive function in their various patient subgroups, with attempts to correlate cognitive decline to APOE {epsilon}4 allele and N-acetylaspartate levels?

Alan A. Mazurek, MD
Rockville Centre, NY

1. Enzinger C, Ropele S, Strasser-Fuchs S, et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E e4 allele. Arch Neurol. 2003;60:65-70. FREE FULL TEXT
2. Chapman J, Vinokurov S, Achiron A, et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology. 2001;56:312-316. FREE FULL TEXT
3. Jessen F, Block W, Traber F, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology. 2001;57:930-932. FREE FULL TEXT
4. Block W, Jessen F, Traber F, et al. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol. 2002;59:828-834. FREE FULL TEXT
5. Pan JW, Krupp LB, Elkins LE, Coyle PK. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. Appl Neuropsychol. 2001;8:155-160. FULL TEXT | PUBMED

Arch Neurol. 2004;61:296.


RELATED ARTICLE

Reduced N-acetylaspartate Levels and Cognitive Decline—Reply
Christian Enzinger and Franz Fazekas
Arch Neurol. 2004;61(2):296.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.